National healthcare investor Baird Capital joins existing investors Oak HC/FT, McKesson Ventures and The Blue Venture Fund Atlanta, GA, May 26, 2020 — Oncology Analytics, a leading data analytics and technology-enabled services company dedicated to helping health...
Former Dana-Farber Associate Chief Medical Officer to Lead Company’s Clinical Team and Innovation Strategy
Articles & Press
CheckMate 9LA: Nivolumab and Ipilimumab plus 2 Cycles of Platinum-Doublet Chemotherapy vs. 4 Cycles of Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer
The following article, written by Adam Peele, PharmD, MHA, BCPS, BCOP, Director of Pharmacy Operations at Oncology Analytics, is the second of a four-part series on key trends and findings from the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, held May 29-31, 2020.
KEYNOTE-355: Phase III study of pembrolizumab plus chemotherapy for previously untreated metastatic triple-negative breast cancer
The following article, written by Laura R. Bobolts, Senior Vice President of Pharmacy at Oncology Analytics, is the first of a four-part series on key trends and findings from the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, held in...
Date: October 20-21
Embassy Suites by Hilton
Fort Lauderdale, FL